ChemoID assay for glioblastoma.

Claudio, Pier Paolo; Mathis, Sarah E; Nande, Rounak; Lawrence, Logan; Alberico, Anthony; Julien, Terrence; Mazagri, Rida; Marsh, Robert; Muizelaar, Paul; Denning, Krista L.; Valluri, Jagan

doi:10.1200/jco.2015.33.15_suppl.e13028

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a new drug response assay has been developed, which is called ChemoID ® that tests separately CSCs and bulk tumor cells. This test has been used to predict the most active/appropriate combination of chemotherapy agents to treat cancer patients individually [ 65 , 74 , 75 , 76 ]. Mathis et al used the ChemoID assay to measure the sensitivity and resistance of CSCs and bulk of tumor cells cultured from two biopsies of human ependymoma challenged with several chemotherapy agents.…”

Section: Role Of Cancer Stem Cells In Tumor Chemosensitivity Assaysmentioning

confidence: 99%

Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients

2021

View full text Add to dashboard Cite

Tumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations between the results of these assays and clinical outcomes, they are still not considered routine tests in the care of cancer patients. The correlations between the assays’ results (drug sensitivity or resistance) and the clinical evaluations (e.g., response to treatment, progression-free survival) are highly promising. However, there is still a need to design randomized controlled prospective studies to secure the place of these assays in routine use. One of the best ideas to increase the value of these assays could be the combination of the assay results with the omics technologies (e.g., pharmacogenetics that gives an idea of the possible side effects of the drugs). In the near future, the importance of personalized chemotherapy is expected to dictate the use of these omics technologies. The omics relies on the macromolecules (Deoxyribonucleic acid -DNA-, ribonucleic acid -RNA-) and proteins (meaning the structure) while TCAs operate on living cell populations (meaning the function). Therefore, wise combinations of TCAs and omics could be a highly promising novel landscape in the modern care of cancer patients.

show abstract